Lv1
38 积分 2024-09-19 加入
Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers
1个月前
已关闭
Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials
1个月前
已完结
Anti-Angiogenic Agents Combined with Immunotherapy for AdvancedNon-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
1个月前
已完结
RADT-27. EFFICACY AND SAFETY OF ANLOTINIB COMBINED WITH CRANIAL RADIOTHERAPY IN NON-SMALL CELL LUNG CARCINOMA PATIENTS WITH BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS
1个月前
已关闭
Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials
1个月前
已完结
Comparison Of Anlotinib Combined With Docetaxel Versus Single Docetaxel As Second-Line Treatment Beside Radiotherapy For Advanced Non-Small Cell Lung Cancer: Efficacy And Safety
2个月前
已完结
Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study
2个月前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
2个月前
已完结
Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care
5个月前
已完结
Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline
5个月前
已完结
皖公网安备34019202002308
